welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)


Pfizer Inc. (NYSE:PFE) will present initial Phase 1b clinical data on PF-06939926, an investigational gene therapy to potentially treat Duchenne muscular dystrophy (DMD) at the 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference in Orlando, FL. These are preliminary data drawn from a small number of participants in an ongoing study.

Pfizer Presents Initial Clinical Data On Phase 1b Gene Therapy Study For Duchenne Muscular Dystrophy (DMD)

rareRelated